Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with pancreatic cancer that cannot be removed by surgery.

Key facts

Study ID

NCT00837876

Run by

Vanderbilt-Ingram Cancer Center

People needed

37

Starts

2008-10-01

Expected to finish

2012-11-01

Last updated by the study team

2014-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Purchase Cancer Group - Paducah — Paducah, Kentucky, United States
• Erlanger Cancer Center at Erlanger Hospital - Baroness — Chattanooga, Tennessee, United States
• Baptist Regional Cancer Center at Baptist Riverside — Knoxville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center at Franklin — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.